Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $55
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $90 to $55.
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $90 to $55.